What about the competition on COVID 19? It’s very possible ours could be so much better. Look how much money the Pharm companies are getting from the federal government. Do you think they want to give up that? Don’t think so.
Medolife Rx will have a huge impact on pharmaceutical competition down the road when they successfully bring their cancer treatments through clinical trials in the USA.
Medolife Rx Breaks Ground on Lab Facility and Increases Scorpion Count at First-of-Its-Kind Reservation in the Dominican Republic The first-of-its-kind reservation is located in a remote area of the DR and is the ideal climate and terrain to support the healthy cultivation of various scorpions. Certain peptides found in scorpions are used in the formulation of many of the Company’s pharmaceutical and nutraceutical products. The facility, which is currently under construction on the reservation, will be approximately 250 square meters and is expandable as needed in order to meet any increases in demand. It will serve as the Company’s cGMP- and ISO-certified research lab where it will extract the peptides and conduct ongoing research and development on the clinical and wellness applications of Escozine® and other formulations. Its addition will decrease the cost of venom production, enabling the Company to lower the final cost of its products, which will increase margins and the marketability of the products. This expansion will increase the reservation’s capacity ten-fold and the Company’s goal is to be able to produce one million doses of Escozine® per month in the near term.
News 
Market Data 
Discover 
AI
